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The pericardial fluid may be representative of the interstitium of the heart. The aim of this
study was to discriminate in cardiovascular disease patients between adipocytokines that
are produced locally by the heart and those supplied by the circulation.
Methods
Enzyme-linked immunosorbent assays (ELISA) were used to determine levels of N-terminal
pro-brain natriuretic peptide (NT-pBNP), fatty acid-binding protein 4 (FABP4), leptin, lipoca-
lin-2, neutrophil elastase, proteinase-3, high sensitivity C-reactive protein (hsCRP) and adi-
ponectin in venous plasma and pericardial fluid harvested during elective cardio-thoracic
surgery (n = 132–152).
Results
In pericardial fluid compared to plasma, the levels were significantly smaller (p < 0.001) for
leptin, lipocalin-2, neutrophil elastase, proteinase-3, hsCRP and adiponectin. For these bio-
markers, the ratio of pericardial fluid-to-plasma level ([PF]/[P], median (interquartile range))
was 0.65 (0.47–1.01), 0.78 (0.56–1.09), 0.23 (0.11–0.60), 0.17 (0.09–0.36), 0.14 (0.08–
0.35), and 0.25 (0.15–0.34), respectively. In contrast, pericardial fluid was significantly
enriched (p < 0.001) in NT-pBNP ([PF]/[P]: 1.9 (1.06–2.73)) and even more so for FABP4
([PF]/[P]: 3.90 (1.47–9.77)). Moreover, in pericardial fluid, the adipocytokines interrelated all
significantly positive and correlated negative to hsCRP, whereas for NT-pBNP only a signifi-
cantly positive correlation with adiponectin was found. These interrelations were distinct
from those in the plasma, as were the correlations of the pericardial biomarkers with patient
characteristics compared to plasma.
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Conclusions
In cardiovascular disease patients, the pericardial cavity is a distinct adipocytokine microen-
vironment in which especially FABP4 is mainly derived from the heart.
Introduction
Adipocytokines are a link between obesity, inflammation and cardiovascular diseases. In obe-
sity, adipose tissue can become dysfunctional, resulting in a change in cellular composition
towards a pro-inflammatory phenotype[1]. Moreover, obesity is characterized by systemic low-
grade inflammation reflected by elevated circulating levels of high sensitivity C-reactive protein
[2]. Most adipocytokines identified in adipose depots are pro-inflammatory and upregulated in
hypertrophic adipose tissue[3] and can via the circulation promote metabolic and cardiovascu-
lar diseases[1]. For instance, patients with coronary artery disease have increased expression of
pro-inflammatory adipocytokines in epicardial adipose tissue compared to non-coronary artery
disease patients, where expression of the anti-inflammatory adiponectin is decreased[4]. We
recently determined the levels of fatty acid-binding protein 4 (FABP4), leptin, and adiponectin
in not only the circulation but also the pericardial fluid from a small number of cardiovascular
disease patients[5]. This fluid can be representative for the interstitium of the heart. Pericardial
fluid contains many bioactive compounds, such as natriuretic peptides, endothelin-1[6] and
angiotensin II[7]. The local concentrations of these signaling molecules are particularly elevated
in cardiovascular disease patients compared to the corresponding plasma levels and can have
direct effects on cardiac function. Current knowledge of the composition and potential patho-
physiological or diagnostic significance of the pericardial fluid is, however, incomplete.
The aim of this study was to discriminate, in cardiovascular disease patients, between locally
produced adipocytokines, related to adipose tissue inflammation and myocardial dysfunction,
measured in the pericardial fluid and those supplied by the circulation. We tested the hypothesis
that the pericardial cavity of cardiovascular disease patients is a unique adipocytokine microen-
vironment, the composition of which can only partly be predicted from the circulation. For
this, levels of FABP4, leptin, lipocalin-2, neutrophil elastase, proteinase-3, and adiponectin were
measured and compared in plasma and pericardial fluid, harvested from a considerably larger
group of patients (compared to previous studies[5, 8–11]) undergoing elective cardiothoracic
surgery. N-terminal pro-brain natriuretic peptide (NT-pBNP) and hsCRP were included as
markers of left ventricular dysfunction[12] and systemic inflammation[13], respectively. In this
cross-sectional observational study, we deliberately included a broad variety of cardiovascular
disease patients to obtain wide ranges of local and circulating adipocytokine concentrations. In
contrast to most previous analyses of human pericardial fluid, we compared in the same indi-
viduals, concentrations in pericardial fluid to those in the venous plasma in order to discrimi-
nate between endocrine and local phenomena. Compared to our previous study[5], the novelty
of the present work includes: i) a four times larger study population, ii) measurements of eight
(instead of three) biomarkers, iii) attention for not only adipocytokines but also indices of left
ventricular dysfunction and inflammation and iv) analyses of the cross-correlations between
these biomarkers in the circulation and in the local pericardial microenvironment.
Material and methods
Subjects, sampling and ethics
All experiments were performed in accordance with institutional guidelines and were
approved by The Regional Committees on Health Research Ethics for Southern Denmark (S-
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20100044 and S-20140202). Investigations were performed conform the principles outlined in
the Declaration of Helsinki and informed written consent was obtained from all patients prior
to collection of the biopsies and information from their medical records. The day before elec-
tive coronary artery bypass grafting (CABG) and/or cardiac valve replacement (VR) surgery,
peripheral venous blood (5 mL) was drawn into pyrogen-free tubes containing K2EDTA and
aprotinin. Pericardial fluid samples (2–5 mL), also collected in K2EDTA and aprotinin, were
obtained right after median sternotomy and section of the pericardium. All samples were cen-
trifuged (3220 G for ten minutes at 4˚C) and the supernatants were stored at -80˚C until analy-
sis. The patients included in this study were free of pericarditis, pericardial effusion and
pericardial tamponade and only pericardial fluid samples without visible blood contaminants
were considered for analysis. Routine plasma analyses for HbA1c, lipids and creatinine were
performed at the Odense University Hospital Clinical Biochemistry laboratory. Clinical infor-
mation was obtained from the patients’ medical records and patient characteristics were dis-
closed to the researchers after finalization of their data collection. These and general patient
characteristics are summarized in Table 1. The study addressed samples of a total of 159
patients that included the 37 patients from which a small number of characteristics and bio-
marker concentrations were previously reported [5].
Measurements of biomarker concentration
Plasma and pericardial fluid levels of NT-pBNP, FABP4, lipocalin-2, neutrophil elastase, pro-
teinase-3, adiponectin and hsCRP were measured using in-house ELISA kits and a hsCRP
assay, respectively (http://www.pharma.hku.hk/sweb/antibody/ELISA.php), as described[14,
15]. Plasma and pericardial fluid levels of leptin were determined with an ELISA kit from Bio-
vendor Laboratories (Brno, Czech Republic) as described[15]. After 100 times dilution, the
total protein in plasma and pericardial fluid was assayed using Pierce BCA Protein Assay Kit
(# 23225, Thermo Fisher Scientific, Massachusetts, United States) according to the instructions
of the manufacturer. All samples were analysed in duplicate.
Statistics
Continuous variables that were normally distributed (Kolmogorov-Smirnov test) are shown
as mean ± standard deviation (SD). Concentrations of biomarkers and continuous variables
that were not normally distributed are shown as median value and interquartile range. Paired
comparisons between observations in plasma and pericardial fluid of the same individuals
were performed with Wilcoxon matched-pairs signed rank tests. Associations between the lev-
els of biomarkers in plasma and pericardial fluid and between biomarker concentrations and
continuous clinical variables were assessed with Spearman correlation tests. Evaluation
between all categorical clinical variables and biomarker levels were performed using Mann-
Whitney U tests. Statistical analyses were performed with GraphPad Prism v6.05 (GraphPad
Software Inc, San Diego, Ca, USA). Differences and associations were considered statistically
significant at p< 0.05. In the tables and figures, the biomarkers are ranked low to high accord-




Table 1 summarizes characteristics of the study population. The patients underwent coronary
artery bypass (53%), cardiac valve replacement (34%) or both (13%), indicating that 66%
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Table 1. Patient characteristics and biomarker concentrations.
Variable Value Missing information (%)
N 159
CABG / VR / both (%)# 53 / 34 / 13 0
Age (years) 69 (62–74) 0
Male (%) 81 0
Smoking Y / F / N (%) 21 / 49 / 27 3
BMI (kg/m2) 28 ± 4.4 0.6
Systolic BP (mmHg) 137 ± 19 1.3
Diastolic BP (mmHg) 74 ± 13 0.6
Ejection fraction (%) 55 (50–60) 11.3
Known hypertension (%) 64 9.4
Type 2 diabetes (%) 25 6.3
Dyslipidemia (%) 84 1.9
Circulating Diagnostics Value Missing information (%)
HbA1c (mmol/mol) 39 (35–43) 7.5
Total cholesterol (mmol/L) 3.9 (3.3–4.6) 7.5
LDL cholesterol (mmol/L) 2.1 (1.7–2.7) 8.2
HDL cholesterol (mmol/L) 1.1 (0.9–1.3) 7.5
Triglycerides (mmol/L) 1.3 (1.0–1.9) 8.2
Creatinine (μmol/L) 89 (75–101) 2.5
Pericardial fluid concentrations Value Missing information (%)
NT-pBNP (μg/L) 0.48 (0.41–0.85) 4.4
FABP4 (μg/L) 80 (42–194) 5.0
Leptin (μg/L) 11 (5–19) 4.4
Lipocalin-2 (μg/L) 31 (24–43 4.4
Neutrophil elastase (μg/L) 19 (8.8–45) 5.7
Proteinase-3 (μg/L) 8.8 (4.3–17) 5.0
hsCRP (mg/L) 0.32 (0.29–0.45) 4.4
Adiponectin (mg/L) 3.7 (2.4–5.7) 4.4
Total protein (g/L) 25 (21–32) 4.4
Plasma Concentrations Value Missing information (%)
NT-pBNP (μg/L) 0.25 (0.21–0.43) 11.3
FABP4 (μg/L) 20 (10–34) 11.9
Leptin (μg/L) 17 (8.3–29) 11.3
Lipocalin-2 (μg/L) 37 (29–50) 11.3
Neutrophil elastase (μg/L) 66 (53–88) 11.3
Proteinase-3 (μg/L) 46 (34–65) 11.3
hsCRP (mg/L) 3,0 (1,4–4,5) 11.3
Adiponectin (mg/L) 15 (11–23) 11.3
Total protein (g/L) 67 (59–76) 11.3
Medications Value Missing information (%)
ACEI / ARB (%) 29 / 17 0
Aspirin (%) 63 0
β-blocker (%) 57 0
Biguanide (%) 19 0
Ca2+-antagonist (%) 36 0
Diuretic (%) 34 0
(Continued)
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suffered from coronary artery disease. Most patients were elderly (70 years), overweight (BMI
>27), males (81%) previously diagnosed with dyslipidemia (84%), prescribed statins (70%)
and had normal plasma lipid levels. Most had a history of smoking (70% former or current
smoker). Sixty-four percent were hypertensive (defined as mean arterial pressure >105 mmHg
or preoperative antihypertensive pharmacotherapy) and a small fraction had type 2 diabetes
(25%) and was prescribed a biguanide (19%). On average, the study population had a plasma
HbA1c level within normal range (HbA1c < 42 mmol/mol). The creatinine values indicated
normal kidney function. Most patients had been prescribed a combination of low-dose aspirin,
inhibitors of the renin angiotensin system and diuretics.
Pericardial fluid levels of biomarkers
In pericardial fluid, the concentrations of all 8 biomarkers and the total protein concentration
differed significantly from those in the plasma (Fig 1, p< 0.001). Compared to plasma, they
were higher for NT-pBNP and FABP4 but lower for leptin, lipocalin-2, neutrophil elastase,
proteinase-3, hsCRP, adiponectin and total protein. According to calculated pericardial fluid-
to-plasma ratio’s ([PF]/ [P]), median (interquartile range), Fig 2A), NT-pBNP was two times
more abundant in the local microenvironment around the heart than in the circulation ([PF]/
[P], 1.9 (1.06–2.73)) and FABP4 was on average four times enriched in pericardial fluid com-
pared to plasma (3.90 (1.47–9.77)). For leptin and lipocalin-2, concentrations were lower in
pericardial fluid than plasma ([PF]/ [P]: 0.65 (0.47–1.01) and 0.78 (0.56–1.09), respectively).
For the other biomarkers, pericardial fluid concentrations were markedly lower compared to
plasma levels ([PF]/ [P]: neutrophil elastase, 0.23 (0.11–0.60); proteinase-3, 0.17 (0.09–0.36);
hsCRP, 0.14 (0.08–0.35); adiponectin, 0.25 (0.15–0.34). The total protein concentration in
pericardial fluid was 0.37 (0.29–0.47) times that observed in the plasma of the same patients.
When calculating these biomarker concentrations as a fraction of the total protein concentra-
tion of each compartment ([PF]/ [P]total protein, median (interquartile range), Fig 2B), NT-
pBNP was more than 5 times and FABP4 even more than 10 times enriched ([PF]/[P]total protein
(5.4 (2.9–9.4) and (10.6 (4.7–26), respectively). Now, leptin (1.8 (1.3–2.8)) and lipocalin-2 (2.2
(1.6–3.1) also seemed significantly enriched in the pericardial cavity. Neutrophil elastase (0.68
(0.39–1.7)), proteinase-3 (0.51 (0.27–1.04)), hsCRP (0.50 (0.21–0.91)), and adiponectin (0.64
(0.45–0.92)), on the other hand, made up a significantly smaller fraction of the total protein
concentration in pericardial fluid compared to plasma.
Relations between levels of biomarkers
Regardless of the different concentrations in the two compartments, the pericardial fluid con-
centrations correlated positively with the plasma concentrations for each biomarker investi-
gated except NT-pBNP (Fig 3).
Table 1. (Continued)
Statin (%) 70 0
Categorical data are shown as % of the study group, normally distributed continuous variables as mean ± SD, non-
normally distributed continuous variables as median value (interquartile range). #, type of surgery; CABG, coronary
artery bypass surgery; VR, valve replacement; Y; yes. F; former. N; never; BMI, body mass index; BP, blood pressure;
NT-pBNP, N-terminal pro-brain natriuretic peptide; FABP4, fatty acid-binding protein 4; hsCRP, high sensitivity C-
reactive protein; ACEI/ARB, inhibitor of angiotensin converting enzyme or antagonist of angiotensin AT1 receptors.
https://doi.org/10.1371/journal.pone.0206802.t001
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In pericardial fluid, the levels of FABP4, leptin, lipocalin-2, neutrophil elastase, proteinase-3
and adiponectin were positively interrelated and each displayed an inverse correlation to the
local concentrations of hsCRP (Fig 4). In the plasma, no inverse relationships and fewer statis-
tically significant positive relationships were observed (Fig 4). The relationships that were
found in both compartments were those between NT-pBNP and adiponectin, between FABP4
and adiponectin, between FABP4 and leptin, between FABP4 and lipocalin-2, between lipoca-
lin-2 and neutrophil elastase, between neutrophil elastase and proteinase-3, and between lipo-
calin-2 and proteinase-3 (Fig 4).
Fig 1. Venous plasma and pericardial fluid concentrations of NT-pBNP (A), FABP4 (B), leptin (C), lipocalin-2 (D), neutrophil elastase (E), proteinase-
3 (F), hsCRP (G), adiponectin (H) and total protein (I) in cardiac and vascular disease patients (n = 132–152). The box plots illustrate median values,
interquartile range and minimal and maximal concentrations compared by Wilcoxon matched-pairs signed rank test. NT-pBNP, N-terminal pro-brain
natriuretic peptide; FABP4, fatty acid-binding protein 4; hsCRP, high sensitivity C-reactive protein. The proteins were ordered (low to high) according to the
molecular weight of their reported most abundant soluble oligomer.
https://doi.org/10.1371/journal.pone.0206802.g001
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Fig 2. A) Ratios of pericardial fluid-to-plasma level ([PF]/[Plasma], n = 132–152) of putative biomarkers and total protein, and B) ratios of the relative
abundance of these biomarkers in the pericardial fluid and plasma ([PF]/[Plasma]total protein, n = 134–136). Shown are the log2-transformed median
(interquartile range) ratios. NT-pBNP, N-terminal pro-brain natriuretic peptide; FABP4, fatty acid-binding protein 4; hsCRP, high sensitivity C-reactive protein.
The proteins were ordered (low to high) according to the molecular weight of their reported most abundant soluble oligomer.
https://doi.org/10.1371/journal.pone.0206802.g002
Fig 3. Associations between venous plasma and pericardial fluid concentrations of NT-pBNP (A), FABP4 (B), leptin (C), lipocalin-2 (D), neutrophil elastase (E),
proteinase-3 (F), hsCRP (G), and adiponectin (H) in cardiac and vascular disease patients (n = 132–152). The double logarithmic plots by Spearman correlation
illustrate the relationship between pericardial fluid concentrations and circulating levels of the biomarkers. NT-pBNP, N-terminal pro-brain natriuretic peptide; FABP4,
fatty acid-binding protein 4; hsCRP, high sensitivity C-reactive protein; ���, P< 0.001. The proteins were ordered (low to high) according to the molecular weight of
their reported most abundant soluble oligomer.
https://doi.org/10.1371/journal.pone.0206802.g003
Elie et al.; adipocytokines in pericardial fluid
PLOS ONE | https://doi.org/10.1371/journal.pone.0206802 November 5, 2018 7 / 15
Relations to patient properties
In the pericardial cavity, NT-pBNP levels were significantly positively correlated to age and
cardiac valve disease. FABP4 levels correlated positively with plasma creatinine concentra-
tions. Leptin related positively to BMI and circulating triglycerides. Lipocalin-2 correlated pos-
itively to age and plasma creatinine. Neutrophil elastase was positively linked to cardiac valve
disease. Adiponectin correlated negatively with ischemic heart disease, type 2 diabetes, plasma
triglycerides, and use of a biguanide, but positively with age, and circulating HDL cholesterol
(Table 2).
In plasma, NT-pBNP concentrations were inversely correlated with being diabetic, use of
statins and a biguanide. FABP4 was positively linked to cardiac valve disease, age and HDL
cholesterol. Leptin correlated positively with BMI and triglycerides. The concentration of lipo-
calin-2 was positively related to age, creatinine and the use of inhibitors of the renin angioten-
sin system. Neutrophil elastase was negatively linked to HDL cholesterol and biguanide use.
Proteinase-3 was also negatively linked to plasma HDL cholesterol levels, but positively linked
to circulating creatinine. hsCRP was negatively correlated to HDL cholesterol levels whereas
adiponectin was negatively correlated to BMI, type 2 diabetes, HbA1c concentrations, triglyc-
erides and use of statins, but positively to cardiac valve disease, age and HDL cholesterol
(Table 3).
Discussion
The main findings of this study are that i) in the pericardial cavity, the concentrations of all 8
biomarkers significantly differed from those in the plasma with NT-pBNP and FABP4 being
more abundant and the remaining biomarkers less abundant, ii) the pericardial fluid concen-
trations of all biomarkers, except NT-pBNP, correlated positively with their plasma levels, iii)
the pericardial fluid levels of FABP4, leptin, lipocalin-2, neutrophil elastase, proteinase-3 and
adiponectin were strongly interrelated and negatively related to the pericardial fluid
Fig 4. Relationships between the concentrations of biomarkers in pericardial fluid (in blue) and venous plasma (in red) of cardiovascular disease patients.
Statistically significant correlations between continuous variables are indicated by Spearman correlation coefficient and �, p< 0.05; ��, p< 0.01 and ���, p< 0.001.
Peptides and proteins are ordered (left to right and top to bottom) according to the molecular weight of their reported most abundant soluble oligomer. N = 139–152.
NT-pBNP, N-terminal pro-brain natriuretic peptide; FABP4, fatty acid-binding protein 4; Lcn2, lipocalin-2; NE, neutrophil elastase; Prot3, proteinase-3; hsCRP, high
sensitivity C-reactive protein; APN, adiponectin; —, not statistically significant.
https://doi.org/10.1371/journal.pone.0206802.g004
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concentration of hsCRP, whereas in the venous plasma less and only positive interrelationships
were observed, and that iv) pericardial fluid biomarker concentrations correlated with many
patient characteristics for which no correlations were found in the plasma. These findings
demonstrate that the pericardial cavity is a distinct adipocytokine microenvironment and indi-
cate that especially FABP4 is produced by the heart in CVD patients.
Dysfunctional adipose tissue, such as hypertrophic adipose tissue, is associated with
increased release of pro-inflammatory adipocytokines from adipocytes and immune cells[1,
3]. These adipocytokines are recognized as a link between inflammation and cardiovascular
diseases[1]. Elevated circulating hsCRP and pro-inflammatory adipocytokines like FABP4,
leptin and lipocalin-2 increase the risk for cardiovascular disease[1, 13, 18] by not only endo-
crine but also paracrine mechanisms[1]. Especially epicardial adipose tissue displays a patho-
genic phenotype in cardiovascular disease patients[4]. In epicardial adipose tissue, expression
of the anti-inflammatory adiponectin, in turn, is decreased in cardiovascular disease patients
with hypertension[19], suffering from coronary artery disease[4], and in those displaying a
combination of features of the metabolic syndrome[20].
The composition of the pericardial fluid may both reflect and contribute to the pathophysi-
ology of the heart and its coronary vasculature.
We previously obtained suggestive evidence that the pericardial cavity in cardiovascular dis-
ease patients is a pro-inflammatory atherogenic micro-environment, distinct from the plasma
[5]. In the present study, we studied a larger number of adipocytokines with a broad range of
molecular weights from 15 kDa (FABP4) up to� 250 kDa (adiponectin) in a larger number of
patients. NT-pBNP was regarded as a control, exclusively produced by the myocardium[21]
and hsCRP as a marker of systemic inflammation[13], mainly produced by the liver[22].
Table 2. Associations of pericardial fluid levels of biomarkers with patient properties.
Patient property NT-pBNP FABP4 Leptin Lcn2 NE Prot3 hsCRP APN
Surgery type +VR#� ns ns ns +VR#� ns ns +VR#���
Age +0.182� ns ns +0.300��� ns ns ns +0.409���
BMI ns ns +0.396��� ns ns ns ns ns
Type 2 diabetes ns ns ns ns ns ns ns –��
EF� 50% ns ns ns ns ns ns ns ns
Plasma NT-pBNP FABP4 Leptin Lcn2 NE Prot3 hsCRP APN
HbA1c ns ns ns ns ns ns ns ns
HDL cholesterol ns ns ns ns ns ns ns +0.298���
Triglycerides ns ns +0.214� ns ns ns ns –0.199�
Creatinine ns +0.212�� ns +0.310��� ns ns ns ns
Medications NT-pBNP FABP4 Leptin Lcn2 NE Prot3 hsCRP APN
Statin ns ns ns ns ns ns ns ns
ACE/ARB ns ns ns ns ns ns ns ns
Biguanide ns ns ns ns ns ns ns –�
Statistically significant correlations to categorical or continuous variables are indicated as follows:
�, p < 0.05
��, p < 0.01 and
���, p < 0.001.
For continuous variables, the Spearman correlation coefficient is shown as well. NT-pBNP, N-terminal pro-brain natriuretic peptide; FABP4, fatty acid-binding protein
4; Lcn2, lipocalin-2; NE, neutrophil elastase; Prot3, proteinase-3; hsCRP, high sensitivity C-reactive protein; APN, adiponectin; ns, not statistically significant; (+) and
(-), positive and negative correlation; EF, ejection fraction; #, valve replacement (VR) surgery compared to coronary artery bypass grafting (CABG); other abbreviations
as in Table 1.
https://doi.org/10.1371/journal.pone.0206802.t002
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Pericardial fluid was sampled from patients with coronary artery or cardiac valve disease.
During cardiothoracic surgery, opening of the pericardial cavity enables easy and safe sam-
pling of pericardial fluid[5, 8]. Patient characteristics in this study are comparable to other
studies reporting on pericardial fluid composition[5, 8–11]. Comparison of venous plasma
from the day before surgery with the pericardial fluid at initiation of surgery is justified
because previous reports have indicated that levels may only change after a couple of hours of
surgery[23, 24].
Only a few studies compared pericardial fluid and plasma from patients suffering from
heart failure or coronary artery disease[5, 8–11]. In the present study, the results demonstrate
that the concentration of NT-pBNP, hsCRP and the adipocytokines differ between both com-
partments, where NT-pBNP and FABP4 were more abundant, and the other biomarkers less
abundant in the pericardial fluid. Moreover, the interrelations of the protein biomarkers in the
pericardial cavity were distinct from those in the plasma, as were the correlations of the peri-
cardial biomarkers with patient characteristics compared to plasma. These data strengthen our
conclusion that the pericardial cavity is a distinct micro-environment of the heart.
The pericardial fluid is regarded by some as an ultrafiltrate of the plasma[25], whereas oth-
ers consider it as representative of the cardiac interstitium[26]. The pericardial fluid-to-plasma
ratio, including the ratio as a fraction of the total protein concentration of the investigated pro-
teins showed a strong relationship with molecular weight from a high ratio for small molecules
(8.5 kDa for NT-pBNP, 15 kDa for FABP4, 16 kDa for leptin, and 25 kDa for lipocalin-2) to a
lower ratio with increasing molecular weight (29 kDa for proteinase-3, 29.5 kDa for neutrophil
elastase, 120 kDa for hsCRP, and> 250 kDa for adiponectin). The pericardial fluid-to-plasma
Table 3. Associations of plasma levels of biomarkers with patient properties.
Patient property NT-pBNP FABP4 Leptin Lcn2 NE Prot3 hsCRP APN
Surgery type ns +VR#�� ns ns ns ns ns +VR#���
Age ns +0.192� ns +0.183� ns ns ns +0.346���
BMI ns ns +0.312��� ns ns ns ns –0.344���
Type 2 diabetes –�� ns ns ns ns ns ns –���
EF� 50% ns ns ns ns ns ns ns ns
Plasma NT-pBNP FABP4 Leptin Lcn2 NE Prot3 hsCRP APN
HbA1c ns ns ns ns ns ns ns –0.275���
HDL cholesterol ns +0.188� ns ns –0.287��� –0.234�� –0.329��� +0.479���
Triglycerides ns ns +0.233�� ns ns ns ns –0.399���
Creatinine ns ns ns +0.508��� ns +0.201� ns ns
Medications NT-pBNP FABP4 Leptin Lcn2 NE Prot3 hsCRP APN
Statin –� ns ns ns ns ns ns –���
ACE/ARB ns ns ns +� ns ns ns ns
Biguanide –� ns ns ns –�� ns ns –���
Statistically significant correlations to categorical or continuous variables are indicated as follows
�, p < 0.05
��, p < 0.01 and
���, p < 0.001.
For continuous variables, the Spearman correlation coefficient is shown as well. Peptides and proteins are ordered (left to right and top to bottom) according to the
molecular weight of their reported most abundant soluble oligomer. NT-pBNP, N-terminal pro-brain natriuretic peptide; FABP4, fatty acid-binding protein 4; Lcn2,
lipocalin-2; NE, neutrophil elastase; Prot3, proteinase-3; hsCRP, high sensitivity C-reactive protein; APN, adiponectin; ns, not statistically significant; + and–, positive
and negative correlation; EF, ejection fraction; #, valve replacement (VR) surgery compared to coronary artery bypass grafting (CABG); other abbreviations as in
Table 1.
https://doi.org/10.1371/journal.pone.0206802.t003
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ratio was larger than one for NT-pBNP. This was expected for a molecule that is predominantly
produced by the myocardium[21]. It was also comparatively large for leptin and lipocalin-2 with
ratios of 0.65 and 0.78 resp. which from the point of view of an ultrafiltrate (ratio of 0.25) cannot
be regarded as such. These proteins can be produced by not only adipocytes but also cardiomyo-
cytes and coronary smooth muscle cells especially in heart failure[27–30]. The largest pericardial
fluid-to-plasma ratio was, however, observed for FABP4, which is in line with recent observa-
tions by Furuhashi et al. of FABP4 in human epicardial adipose tissue and coronary atheroscle-
rotic plaques and of higher levels of FABP4 in the coronary sinus compared to the aortic root
[31]. Moreover, the ratios as a fraction of the total protein were even higher, ranging between
1.8 for leptin and 10.6 for FABP4, strongly indicating cardiac production of also these adipocy-
tokines. Conversely, the pericardial fluid-to-plasma ratio, including the ratio as a fraction of
total protein was very low for adiponectin although it can be produced by epicardial adipose tis-
sue[4, 19, 20] and cardiomyocytes[32]. It is not likely that this is due to the large molecular
weight of adiponectin complicating its diffusion over the epicardial mesothelium. We previously
reported a similar contribution of high molecular weight adiponectin to the total concentration
of adiponectin in pericardial fluid and venous plasma[5]. Rather, the pro-inflammatory adipocy-
tokine environment in the pericardial cavity/cardiac interstitium might suppress local produc-
tion of adiponectin [4, 33, 34] and thereby limit cardiovascular protective effects.
hsCRP, an important risk factor and independent predictor of cardiovascular events[13] is
mainly produced by the liver[22] but can also be expressed by human adipocytes[33] and
immune cells[35]. In this study, circulating levels of hsCRP were positively related to those of
the strongly interrelated neutrophil markers proteinase-3 and neutrophil elastase[36, 37] as
reported before[38]. In the pericardial fluid, on the other hand, the concentration of hsCRP was
inversely related to that of the still strongly interrelated proteinase-3 and neutrophil elastase.
This suggests local proteolysis[39] and increased local permeability of hsCRP, by the neutrophil
enzymes. The local concentration of other large molecular weight proteins like leptin and lipo-
calin-2, but not the small peptide fragment NT-pBNP, seems to be similarly affected (Fig 4).
In the systemic circulation of coronary artery disease[40] or heart failure patients[41], levels
of NT-pBNP and of adiponectin are positively related independently from systemic inflamma-
tion. In our study of a broadly diverse group of patients, we confirmed this association in the
venous plasma and observed it for the first time in the pericardial fluid. Natriuretic peptides
have favorable effects on the distribution of adipose tissues in the body[42] and on the pheno-
type of adipocytes[43]. They stimulate the production of adiponectin by cultured human adi-
pocytes[44] and increase the circulating levels of total and high molecular weight adiponectin
when infused into the body[45]. Conversely, cardiomyocytes express low levels of adiponectin
and its receptors[32] that are increased under experimental pathological conditions[46]. Also,
adiponectin decreases cardiomyocyte hypertrophy and BNP mRNA expression[47] and
reduces myocardial oxidative stress[48]. These and our present observations indicate both sys-
temic and local interaction between a sign of myocardial dysfunction[21] and an adipocyte-
derived cardiovascular protective and anti-inflammatory endocrine and paracrine mediator
[18, 48]. Interplay between adipocytokines and inflammatory signals seem however to differ
between locations as we observed strong interrelations of the levels of FABP4, lipocalin-2, pro-
teinase-3 and neutrophil elastase in pericardial fluid/cardiac interstitium and to a much lesser
extent in the circulation (Fig 4).
Study limitations and perspectives
Our study is a cross-sectional observational study in very diverse patients with the aim to
obtain broad ranges of local and circulating concentrations of adipocytokines and markers of
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heart failure and inflammation. For obvious ethical reasons, pericardial fluid could not be
obtained from healthy volunteers. Our results may therefore be affected by for instance pres-
ence of comorbidities or the severity of chronic cardiovascular condition. The associations
that we identified could be accidental and coincident rather than indicative of causal relation-
ships. We determined pericardial fluid concentrations but could not consider the volume of
the pericardial fluid. Echocardiography information on the pericardial space[10] was not avail-
able. Analyses of relations to patient demographic, diagnostic and pharmacotherapeutic char-
acteristics were superficial at this stage.
Despite these limitations, our suggestive evidence of the pericardial space as a distinct adi-
pocytokine micro-environment adds to the proposal that the pericardial space holds potential
for improved diagnosis and local treatment[49]. It invites for more extensive proteomic analy-
ses[50] that address pathophysiological and therapeutic mechanisms of coronary and cardiac
diseases. Future studies may specifically focus on coronary large artery disease, coronary
microvascular disease or heart failure and on the severity of these conditions.
In conclusion, the results demonstrate significant differences of the concentrations of all
biomarkers investigated between the pericardial fluid and plasma, and significant different
interplays between adipocytokines and inflammatory signals within each fluid compartment,
indicating that the pericardial cavity is a distinct micro-environment of the heart in which lep-
tin, lipocalin-2 and especially FABP4 seem to be derived from the heart.
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